Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CBL |
| Variant | Y455_D456del |
| Impact List | deletion |
| Protein Effect | unknown |
| Gene Variant Descriptions | CBL Y455_D456del results in the deletion of two amino acids of the Cbl protein from amino acids 455 to 456 (UniProt.org). Y455_D456del has been identified in sequencing studies (PMID: 25017477), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Aug 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
CBL mutant CBL exon9 CBL Y455_D456del |
| Transcript | NM_005188.4 |
| gDNA | chr11:g.119278645_119278650delTATGAT |
| cDNA | c.1363_1368delTATGAT |
| Protein | p.Y455_D456delYD |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_005188 | chr11:g.119278645_119278650delTATGAT | c.1363_1368delTATGAT | p.Y455_D456del | RefSeq | GRCh38/hg38 |
| NM_005188.3 | chr11:g.119278645_119278650delTATGAT | c.1363_1368delTATGAT | p.Y455_D456del | RefSeq | GRCh38/hg38 |
| XM_011543057 | chr11:g.119278645_119278650delTATGAT | c.1363_1368delTATGAT | p.Y455_D456del | RefSeq | GRCh38/hg38 |
| NM_005188.4 | chr11:g.119278645_119278650delTATGAT | c.1363_1368delTATGAT | p.Y455_D456delYD | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CBL mutant | systemic mastocytosis | not applicable | N/A | Guideline | Prognostic | CBL mutations are associated with an adverse prognosis in patients with systemic mastocytosis (NCCN.org). | detail... |
| CBL mutant | myelofibrosis | not applicable | N/A | Guideline | Prognostic | CBL mutations are associated with inferior overall survival in patients with primary myelofibrosis (NCCN.org). | detail... |
| CBL mutant | bone marrow cancer | sensitive | Quizartinib | Preclinical | Actionable | In a preclinical study, Vanflyta (quizartinib) reduced white blood cell counts and decreased myeloid cell invasion in a CBL mutant mouse model with myeloproliferative disorder (PMID: 22990016). | 22990016 |
| CBL mutant | myelodysplastic/myeloproliferative neoplasm | not applicable | N/A | Clinical Study | Prognostic | In clinical analyses, mutations in CBL were associated with adverse prognosis in patients with chronic myelomonocytic leukemia (PMID: 26230957, PMID: 23690417, PMID: 19901108). | 26230957 19901108 23690417 |